Previous 10 | Next 10 |
2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...
2023-04-25 22:20:34 ET Summary Positive Phase 2a data: MORF-057 demonstrated a statistically significant reduction in RHI score and a clinical remission rate of 25.7% (mMCS), supporting our bullish thesis on Morphic Therapeutic. Promising safety results: The absence of serious saf...
2023-04-25 13:24:38 ET For further details see: Morphic Holding down 10% despite bottom line earnings beat
2023-04-25 10:06:07 ET Gainers: Baudax Bio ( BXRX ) +48% . Petros Pharmaceuticals ( PTPI ) +48% . Morphic Holding ( MORF ) +22% . Arrowhead Pharmaceuticals ( ARWR ) +17% . Medpace Holdings ( MEDP ) +17% . Losers: Trac...
2023-04-25 08:56:00 ET Morphic press release ( NASDAQ: MORF ): Q1 GAAP EPS of $0.90 beats by $1.71 . Revenue of $0.5M (-79.0% Y/Y) misses by $1.66M . As of March 31, 2023, Morphic had cash, cash equivalents and marketable securities of $421 million, compared to...
2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) +74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) +34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) +32% . ZeroFox ...
2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) -74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) -34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) -32% . ZeroFox ...
2023-04-25 07:35:55 ET Morphic Holding ( NASDAQ: MORF ) added ~38% pre-market Tuesday after announcing that its lead candidate MORF-057 reached the primary endpoint in a mid-stage trial for adults with ulcerative colitis (UC). The EMERALD-1 Phase 2a trial enrolled 35 patient...
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical remission by Modified Mayo Clinic Score (mMCS)- -MORF-057 generally well tolerated with ...
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed- -EMERALD-2 Phase 2b Trial of MORF-057 progressing on track- ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...